Effect of B-Type Natriuretic Peptide Level on Long-Term Outcome in Patients With End-Stage Heart Failure

2016 ◽  
Vol 118 (3) ◽  
pp. 383-388 ◽  
Author(s):  
Bi Huang ◽  
Jian Shen ◽  
Lihua Li ◽  
Ying Huang ◽  
Suxin Luo
2021 ◽  
Author(s):  
Aiju Tian ◽  
Chengzhi Yang ◽  
Shengfeng Weng ◽  
Xiaoli Chen ◽  
Hong Liu ◽  
...  

Abstract Background Previous studies have shown that heart failure is associated with hemostatic abnormalities and hypercoagulable state. Plasma D-dimer levels reflect both fibrin formation and degradation, and elevated D-dimer levels have been associated with poor prognosis in patients with heart failure. However, little is known about their roles in elderly patients with end-stage HF. In present study, we aimed to explore the clinical significance and determinants of plasma D-dimer in elderly patients with end-stage heart failure. Methods A total of 177 patients with heart failure at Beijing Geriatric Hospital from November 1, 2015 to December 30, 2018 were enrolled. All hospitalized patients were obtained D-dimer levels within the first 24 h following admission after obtaining informed consent. Primary endpoint was all-cause mortality. Results A total of 60 patients had elevated D-dimer levels. Blood urea nitrogen (β = 1.106, 95% CI: 1.029–1.190, p = 0.006), NYHA functional class (β = 2.179, 95% CI: 1.170–4.056, p = 0.014) and white blood cell counts (β = 1.188, 95% CI: 1.040–1.358, p = 0.011) were independent risk factors for elevated D-dimer in elderly patients with end-stage heart failure. Albumin (β = 0.803, 95% CI: 0.728–0.885, P ༜ 0.001) was negative risk factor for elevated D-dimer in elderly patients with end-stage heart failure. Elevated D-dimer level was independently associated with increased risk of long-term all-cause mortality (P = 0.048). Conclusions For elderly patients with end-stage heart failure, D-dimer levels were associated with white blood cell counts, blood urea nitrogen, albumin and NYHA functional class and elevated D-dimer level was independently associated with poor long-term outcome.


2021 ◽  
Author(s):  
Aiju Tian ◽  
Chengzhi Yang ◽  
Shengfeng Weng ◽  
Xiaoli Chen ◽  
Hong Liu ◽  
...  

Abstract Background: Previous studies have shown that heart failure is associated with hemostatic abnormalities and hypercoagulable state. Plasma D-dimer levels reflect both fibrin formation and degradation, and elevated D-dimer levels have been associated with poor prognosis in patients with heart failure. However, little is known about their roles in elderly patients with end-stage HF. In present study, we aimed to explore the clinical significance and determinants of plasma D-dimer in elderly patients with end-stage heart failure. Methods: A total of 177 patients with heart failure at Beijing Geriatric Hospital from November 1, 2015 to December 30, 2018 were enrolled. All hospitalized patients were obtained D-dimer levels within the first 24 h following admission after obtaining informed consent. Primary endpoint was all-cause mortality. Results: A total of 60 patients had elevated D-dimer levels. Blood urea nitrogen (β=1.106, 95% CI: 1.029-1.190, p = 0.006), NYHA functional class (β=2.179, 95% CI: 1.170-4.056, p = 0.014) and white blood cell counts (β = 1.188, 95% CI: 1.040-1.358, p = 0.011) were independent risk factors for elevated D-dimer in elderly patients with end-stage heart failure. Albumin (β=0.803, 95% CI: 0.728-0.885, P < 0.001) was negative risk factor for elevated D-dimer in elderly patients with end-stage heart failure. Elevated D-dimer level was independently associated with increased risk of long-term all-cause mortality (P = 0.048). Conclusions: For elderly patients with end-stage heart failure, D-dimer levels were associated with white blood cell counts, blood urea nitrogen, albumin and NYHA functional class and elevated D-dimer level was independently associated with poor long-term outcome.


Author(s):  
Finn Gustafsson ◽  
Kasper Rossing

Heart transplantation remains the treatment of choice for end-stage heart failure refractory to conventional treatment. Long-term outcome is excellent, and median survival currently exceeds 13 years. The main causes of death late after transplantation are cardiac allograft vasculopathy and cancer. Medical therapy after transplantation is complex, including immunosuppressive therapy to reduce the risk of graft rejection and prophylaxis against viral and protozoal infections, as well as adjunctive therapy to treat common comorbidities, for instance hypertension. Pharmacological therapy of comorbid conditions requires specific consideration to clinically important interactions with immunosuppressive drugs.


Author(s):  
Finn Gustafsson ◽  
Kasper Rossing

Heart transplantation remains the treatment of choice for end-stage heart failure refractory to conventional treatment. Long-term outcome is excellent, and median survival currently exceeds 13 years. The main causes of death late after transplantation are cardiac allograft vasculopathy and cancer. Medical therapy after transplantation is complex, including immunosuppressive therapy to reduce the risk of graft rejection and prophylaxis against viral and protozoal infections, as well as adjunctive therapy to treat common comorbidities, for instance hypertension. Pharmacological therapy of comorbid conditions requires specific consideration to clinically important interactions with immunosuppressive drugs.


Sign in / Sign up

Export Citation Format

Share Document